News Related to NMIBC Carcinoma In Situ

Related coverage linked through entity extraction aliases.

ImmunityBio Secures EU Authorization for ANKTIVA, Expands to 33 Countries

Feb 19, 2026

The European Commission granted conditional marketing authorization for ANKTIVA in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer, expanding the therapy's availability to 33 countries across four regulatory jurisdictions.

ImmunityBio Partners with Accord Healthcare to Expand Anktiva Access Across 33 Countries

Feb 19, 2026

ImmunityBio has partnered with Accord Healthcare to expand access to Anktiva across 30 countries following conditional EU authorization. The company established an Irish subsidiary to support European distribution and commercialization.